EMF / ROS Cancer Research Results

RF, EMF: Click to Expand ⟱

Features:

radiofrequency (RF) electromagnetic fields (EMF)

-example 27.12 MHz https://www.therabionic.com/ TheraBionic P1

Radiofrequency electromagnetic fields — non-ionizing electromagnetic fields within the radiofrequency spectrum that can be delivered using highly divergent exposure configurations, including low-power amplitude-modulated systemic fields, transcranial fields, localized dielectric heating, thermal ablation, and nanoparticle-assisted RF treatment. RF electromagnetic field therapy is a physical medical-device modality rather than a drug; standard abbreviations include RF, RF-EMF, AM RF-EMF for amplitude-modulated RF fields, and TEMT for transcranial electromagnetic treatment. For this database entry, the most relevant anticancer implementation is the non-thermal TheraBionic platform, which uses a 27.12 MHz carrier amplitude-modulated at tumor-specific low frequencies and delivered through an intraoral antenna. This modality must not be conflated with thermal radiofrequency ablation, RF hyperthermia, tumor-treating fields, microwave ablation, or ordinary environmental RF exposure because their field strengths, frequencies, tissue interactions, and clinical evidence differ substantially.

Primary mechanisms (ranked):

Tumor-specific modulation-frequency sensing followed by selective disruption of cancer-cell proliferation and mitosis.
CaV3.2 T-type calcium-channel engagement with altered Ca²⁺ influx and downstream IP3, DAG, and calcium-dependent signaling.
Mitotic-spindle and chromosome-segregation disruption, producing mitotic arrest or abnormal mitotic progression.
Altered PLK1-associated mitotic signaling and suppression of clonogenic tumor-cell growth.
Context-dependent differentiation, apoptosis, or non-apoptotic loss of viability after prolonged repeated exposure.
ROS modulation is secondary and inconsistent across RF exposure systems; it is not a sufficiently established core mechanism for tumor-specific AM RF-EMF therapy.

Bioavailability / PK relevance: Conventional pharmacokinetics do not apply. Biological exposure depends on carrier frequency, modulation frequencies, electric-field strength, specific absorption rate, antenna coupling, tissue conductivity, treatment duration, duty cycle, body geometry, and field distribution. The TheraBionic P1 is administered for one hour three times daily through an antenna placed in the mouth, producing low-level systemic RF exposure. Clinical translation cannot be inferred from frequency alone.

In-vitro vs systemic exposure relevance: RF-EMF effects are not concentration-driven. In-vitro findings are relevant only when carrier frequency, modulation pattern, field amplitude, dosimetry, temperature, exposure duration, antenna geometry, and electromagnetic compatibility are reproduced. Results from high-power or thermally confounded systems cannot be extrapolated to low-power non-thermal tumor-specific AM RF-EMF exposure.

Clinical evidence status: FDA humanitarian-device authorization with limited clinical evidence. TheraBionic P1 received US Humanitarian Device Exemption approval for adults with advanced hepatocellular carcinoma that has failed first- and second-line systemic therapy. The authorization is based on probable benefit rather than the conventional reasonable-assurance-of-effectiveness standard and requires post-approval evaluation. Evidence for other cancers remains preclinical, compassionate-use, case-series, or early clinical research. This broad RF entry should therefore be classified as clinically deployed for a narrow HCC indication, but investigational for most other systemic anticancer uses.

RF-EMF Anticancer Mechanisms

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Tumor-specific frequency response	Proliferation ↓	Proliferation ↔	G	Selective growth inhibition	Reported for defined amplitude-modulation frequencies superimposed on a 27.12 MHz carrier; frequency specificity remains incompletely characterized and is device-dependent.
2	CaV3.2 calcium-channel signaling	Ca²⁺ signaling altered	Uncertain	P R	Signal transduction and differentiation	CaV3.2 involvement has been demonstrated principally in hepatocellular carcinoma models and should not be generalized to all cancers or RF systems.
3	IP3 and DAG signaling	IP3 ↑ DAG ↑	Uncertain	P R	Calcium-dependent antiproliferative signaling	Downstream response associated with tumor-specific AM RF-EMF exposure and CaV3.2-dependent signaling.
4	Mitotic spindle integrity	Spindle organization ↓ Chromosome segregation abnormal	Limited change reported	R G	Mitotic disruption	Observed in HCC and more recently in glioblastoma models; biological relevance depends on tumor-specific modulation frequencies.
5	PLK1-associated mitotic signaling	PLK1 pathway altered	Uncertain	R G	Mitotic arrest and reduced clonogenicity	Direction can vary by sampling time because pathway activation may represent mitotic stress rather than productive proliferation.
6	Cell differentiation	Differentiation ↑	↔	G	Reduced malignant phenotype	Strongest evidence is in HCC models and is linked experimentally to CaV3.2 signaling.
7	Cell-cycle progression	Cell-cycle progression ↓	Limited effect reported	G	Growth arrest	Repeated exposure is generally required; effects are not equivalent to acute RF heating.
8	Apoptosis and cell viability	Apoptosis ↑ Viability ↓	Viability ↔	G	Tumor-cell loss	Magnitude and death phenotype are model-dependent; growth arrest may predominate over rapid cytotoxicity.
9	Oxidative stress	ROS ↑ or ↔ (context-dependent)	ROS ↑, ↓, or ↔ (exposure-dependent)	P R G	Secondary stress response	Results across the RF literature are heterogeneous and often depend on power, temperature, cell type, exposure chamber, and dosimetry. ROS should not be presented as a universal RF anticancer mechanism.
10	Chemosensitization	Drug response ↑ (model-dependent)	Uncertain	G	Potential adjunct activity	Combination evidence is preliminary and cannot yet support a general clinical chemosensitizer classification.
11	Clinical Translation Constraint	Response heterogeneous	Low reported toxicity for the authorized device	G	Restricted clinical generalizability	Effects depend on device-specific modulation frequencies, coupling, dosimetry, treatment adherence, tumor identity, and field geometry. FDA authorization applies only to advanced HCC after failure of first- and second-line therapy and was based on limited probable-benefit evidence.

P: 0–30 min R: 30 min–3 hr G: >3 hr

Radiofrequency electromagnetic fields in Alzheimer’s disease — transcranial RF-EMF systems such as transcranial electromagnetic treatment deliver repeated non-ionizing fields through multiple emitters positioned around the head. Experimental systems generally use RF exposure intended to remain below tissue-heating thresholds. Proposed effects include interference with amyloid-β aggregation, enhancement of mitochondrial function, altered neuronal bioenergetics, and possible changes in cerebral perfusion. This application is distinct from both the TheraBionic cancer device and transcranial magnetic stimulation.

Primary mechanisms (ranked):

Destabilization or reduced accumulation of soluble and aggregated amyloid-β species.
Improved mitochondrial electron-transport function, membrane potential, and ATP production.
Possible enhancement of cerebral blood flow and neuronal metabolic activity.
Secondary modulation of oxidative stress and inflammatory signaling.

Bioavailability / PK relevance: Pharmacokinetics do not apply. Relevant variables include carrier frequency, specific absorption rate, emitter arrangement, skull and tissue conductivity, treatment duration, and intracranial field uniformity.

In-vitro vs systemic exposure relevance: RF effects are not concentration-driven. Cell-culture, mouse, and human results cannot be compared without matched dosimetry and thermal controls. Amyloid effects reported under one RF protocol do not establish a general effect of environmental RF exposure.

Clinical evidence status: Small human feasibility studies only. Early open-label trials reported acceptable short-term tolerability and exploratory cognitive or biomarker signals, but the samples were very small and lacked adequate blinded randomized controls. Extension studies have been registered, but RF-EMF is not an approved Alzheimer’s disease treatment and efficacy remains unproven.

RF-EMF Mechanisms in Alzheimer’s Disease

Rank	Pathway / Axis	Modulation	TSF	Primary Effect	Notes / Interpretation
1	Amyloid-β aggregation and clearance	Aβ oligomers ↓ Aβ deposition ↓	G	Reduced amyloid burden	Supported mainly by cell-culture and transgenic-mouse studies; human biomarker confirmation remains limited.
2	Mitochondrial electron transport	ETC function ↑ Membrane potential ↑	R G	Improved neuronal bioenergetics	Preclinical evidence suggests mitochondrial effects may contribute to cognitive changes.
3	ATP production	ATP ↑	R G	Improved cellular energy availability	Evidence is predominantly preclinical and protocol-specific.
4	Cerebral perfusion	Blood flow ↑ (region-dependent)	R G	Improved metabolic support	Regional perfusion changes have been reported, but clinical importance is uncertain.
5	Oxidative stress	ROS ↓ or ↑ (context-dependent)	P R G	Secondary redox modulation	Beneficial and adverse redox effects have both been described under different RF protocols; exposure parameters are decisive.
6	Cognition and memory	Cognition ↑ (preliminary)	G	Possible functional improvement	Signals derive from animal studies and very small uncontrolled human studies; efficacy is not established.
7	Clinical Translation Constraint	Evidence limited	G	Investigational status	Small cohorts, open-label designs, heterogeneous RF protocols, incomplete sham control, uncertain durability, and absence of regulatory approval prevent clinical efficacy conclusions.

P: 0–30 min R: 30 min–3 hr G: >3 hr

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

5975-

AgNPs,

PDT,

CDT,

RF,

Recent Advances in the Application of Silver Nanoparticles for Enhancing Phototherapy Outcomes

Review,

Var,

Review,

BPH,

ROS↑, EPR↓, eff↑, Bacteria↓, eff↑, eff↑, TumVol↓,

6813-

RF,

The effect of superposition of 900 MHz and incoherent noise electromagnetic fields on the induction of reactive oxygen species in SP2/0 cell line

in-vitro,

Melanoma,

SP2/0

ROS↑,

6811-

RF,

Continuous Exposure to 1.7 GHz LTE Electromagnetic Fields Increases Intracellular Reactive Oxygen Species to Decrease Human Cell Proliferation and Induce Senescence

in-vitro,

Liver,

HUH7

in-vitro,

Liver,

Hep3B

in-vitro,

Cerv,

HeLa

in-vitro,

neuroblastoma,

SH-SY5Y

in-vitro,

Nor,

IMR90

TumCP↓, eff↑, ROS↑, eff↓,

4570-

RF,

Role of Mitochondria in the Oxidative Stress Induced by Electromagnetic Fields: Focus on Reproductive Systems

Review,

Nor,

*ETC↓, *ROS↑, *ROS∅,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,
Total Targets: 7

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1, ROS∅, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

ETC↓, 1,
Total Targets: 3

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

4 EMF
1 Silver-NanoParticles
1 Photodynamic Therapy
1 chemodynamic therapy

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:329  Target#:275  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

EMF / ROS Cancer Research Results

RF-EMF Anticancer Mechanisms

RF-EMF Mechanisms in Alzheimer’s Disease

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Home Page